Table 2.
Summary of applicability (availability) of drugs, equipment and testing according to Asian country
| Drugs/equipment | CSCO |
ISMPO |
JSMO |
KSMO |
MOS |
SSO |
TOS |
|---|---|---|---|---|---|---|---|
| Available Y/N | Available Y/N | Available Y/N | Available Y/N | Available Y/N | Available Y/N | Available Y/N | |
| Laparoscopic RN | Y | Y | Y | Y | Y | Y | Y |
| RFA, MWA or CA | Y | Y | N | Y | Y | Y | Y |
| VMAT or SBRT | Y | Y | Y | Y | Y | Y | Y |
| SRS | Y | Y | Y | Y | Y | Y | Y |
| Tivozanib | N | N | N | N | N | N | N |
| Axitinib and pembrolizumab | Y | Y | Y | Y | Y | Y | Y |
| Ipilimumab and nivolumab | Y | Y | Y | Y | N | Y | Y |
| Cabozantinib | Y | N | Y | Y | N | Y | Y |
| Cabozantinib and nivolumab | Y | Y | N | N | N | Y | Y |
| Lenvatinib and everolimus | Y | Y | N | Y | Y | Y | Y |
| Lenvatinib and pembrolizumab | N | Y | N | Y | Y | Y | Y |
CA, cryoablation; CSCO, Chinese Society of Clinical Oncology; ISMPO, Indian Society of Medical and Paediatric Oncology; MWA, microwave ablation; JSMO, Japanese Society of Medical Oncology; KSMO, Korean Society of Medical Oncology; RFA, radiofrequency ablation; RN, radical nephrectomy; SBRT, stereotactic body radiotherapy; SRS, stereotactic radiosurgery; SSO, Singapore Society of Oncology; TOS, Taiwan Oncology Society; VMAT, volumetric-modulated arc therapy.